Search Contact
Patients with mental health problems treated with Neurofarmagen experience a reduction in adverse effects and respond to treatment quicker and more effectively
13 January 2020

The Christmas holidays that have just passed were a cause for celebration for many people, but for many others it could have contributed to the worsening of pathologies such as depression or anxiety. That is why it is essential not to abandon treatments and have the additional help of medical professionals who can establish the necessary steps to improve treatment for these conditions.

The biotechnology company AB-Biotics has created Neurofarmagen®, a high-precision medical tool that uses the patient’s own characteristics (genetic profile, age, gender, diet, diseases and treatments, etc.) to select and guide the prescription of Psychiatric drugs in adult patients with depression, anxiety, OCD, schizophrenia, ADHD, bipolarity, among others. A meta-analysis, recently published in the Pharmaceutical Journal, combines the results of three clinical studies carried out with Neurofarmagen® on adult patients with depression and demonstrates that the use of this pharmacogenetic tool improves treatment efficacy, with a probability approximately two times higher of successful treatment when using this precision medical tool.

Neurofarmagen® is available to neuropsychiatric patients who wish to improve the efficacy of their treatment, whether due to lack of response to medication, tolerance problems, use of a large number of drugs and / or in the case of especially sensitive patients. With only a simple saliva sample, this test can provide the doctor with the most suitable pharmacological treatment as well as the most appropriate dosage for each patient, contributing to a greater probability of therapeutic success. This will lead to a decrease in adverse effects, shorten the response time to treatment and decrease the number of required visits to the specialist.

“What we see in our clinical studies is that the use of Neurofarmagen increases the percentage of patients who respond favorably to medication and decreases the percentage of patients who suffer from adverse effects, which can result in an increase in the patient’s adherence to treatment (follow-up).” explained the CEOs of AB-Biotics, Miquel Ángel Bonachera and Sergi Audivert.

According to the National Health Survey of Spain (ENSE, 2017), 10.8% of respondents aged 15 or over reported having been diagnosed with a mental health problem, with women suffering more often from these type of disorders (14.1% of women versus 7.2% of men). 6.7% of adults reported being diagnosed with depression and the same percentage were diagnosed with chronic anxiety. Depression was reported more than twice as often in women (9.2%) than in men (4%).

The prevalence of depression is higher amongst unemployed people (7.9%) than those who work (3.1%), and reaches a level of 30% in people who are unable to work.

 Annual cost in Spain

The annual expenditure in Spain on mental disorders was estimated at around 46 billion (UK) euros, according to a study published in 2014 in the journal Plos One. The annual cost per patient varies depending on the pathology. In the case of mental disorders, it ranges from €3,584 per patient for mood disorders (including depression and bipolar disorder) and €17,576 per patient for psychotic disorders.

In a study conducted on patients with bipolar disorder in Italy by Dr. Camilla Callegari and his team (from the University of Insubria, Varese), the results were compared in economic terms (using the number and duration of hospitalizations as indicators, and use of emergency services) the 12 months prior to beginning treatment with Neurofarmagen® and for the subsequent 12 months. Considerable savings were established. The costs related to the hospitalization of these 30 patients during the year prior to the test were around €148,920, while in the subsequent year it decreased to around €10,548 (€39,048 if the cost of Neurofarmagen® is factored in).